4.7 Article

Ultrasonic Microbubble Cavitation Deliver Gal-3 shRNA to Inhibit Myocardial Fibrosis after Myocardial Infarction

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Biochemistry & Molecular Biology

Galectin-3 interferes with tissue repair and promotes cardiac dysfunction and comorbidities in a genetic heart failure model

Fani Vlachou et al.

Summary: Galectin-3 plays a role in promoting cardiac adverse remodeling, inflammation, and failure by affecting functions of cardiac fibroblasts and macrophages. This study suggests that Galectin-3 is a valid intervention target for treating heart failure and associated comorbidities.

CELLULAR AND MOLECULAR LIFE SCIENCES (2022)

Review Cardiac & Cardiovascular Systems

Angiogenesis after acute myocardial infarction

Xuekun Wu et al.

Summary: The translation describes how acute myocardial infarction causes damage to the coronary microcirculation, leading to vascular disintegration and capillary rarefication in the infarct region. Tissue repair after MI involves robust angiogenic response and interactions among various cell types through secreted proteins and receptors. Macrophages and fibroblasts have emerged as major drivers of the angiogenic response after MI, while understanding the mechanism of infarct angiogenesis creates therapeutic opportunities.

CARDIOVASCULAR RESEARCH (2021)

Article Biochemistry & Molecular Biology

The therapeutic potential of galectin-3 inhibition in fibrotic disease

R. J. Slack et al.

Summary: Galectin-3, a beta-galactoside-binding mammalian lectin, plays a crucial role in regulating cellular signaling by prolonging retention time or retarding lateral movement of cell surface receptors in the plasma membrane. It is involved in various cellular functions such as diffusion, compartmentalization, endocytosis, and the functionality of membrane receptors, and has been shown to be pro-fibrotic in multiple models of organ fibrosis. Additionally, there has been a significant increase in scientific literature investigating the role of Galectin-3 in fibrotic diseases and the clinical development of new Galectin-3 inhibitors over the past decade.

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2021)

Review Pharmacology & Pharmacy

Cardiac fibrosis: Myofibroblast-mediated pathological regulation and drug delivery strategies

Mengrui Liu et al.

Summary: Cardiac fibrosis is a major challenge in heart diseases, with myoFbs playing a key role in the fibrotic process. The lack of clear mechanisms and specific targets poses challenges for treatment strategies.

ADVANCED DRUG DELIVERY REVIEWS (2021)

Article Cardiac & Cardiovascular Systems

Small Endogeneous Peptide Mitigates Myocardial Remodeling in a Mouse Model of Cardioselective Galectin-3 Overexpression

Swati D. Sonkawade et al.

Summary: The study demonstrated that cardioselective Gal3 overexpression leads to cardiac inflammation and fibrosis, ultimately resulting in cardiac dysfunction. Pharmacological inhibition of Gal3 can reduce inflammation and fibrosis, providing protective effects against cardiac dysfunction.

CIRCULATION-HEART FAILURE (2021)

Review Cardiac & Cardiovascular Systems

Cardiac fibrosis

Nikolaos G. Frangogiannis

Summary: Myocardial fibrosis, characterized by the expansion of cardiac interstitium through deposition of extracellular matrix proteins, is a common pathophysiologic feature in various myocardial conditions. Activated fibroblasts and myofibroblasts play a central role in cardiac fibrosis, producing matrix proteins and triggering fibrogenic signalling cascades in response to stress. Immune cells, vascular cells, and cardiomyocytes can also contribute to fibrosis, while fibrotic changes may disrupt cardiac function and play a role in arrhythmogenesis.

CARDIOVASCULAR RESEARCH (2021)

Article Cardiac & Cardiovascular Systems

Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension

Emily S. Lau et al.

Summary: In this trial, higher Gal-3 levels were associated with female sex, diabetes, and reduced glomerular filtration rate in cross-sectional analyses, but treatment with modified citrus pectin did not change collagen markers. Further investigation is needed for the effect of Gal-3 inhibition among individuals with heart failure.

JACC-BASIC TO TRANSLATIONAL SCIENCE (2021)

Review Cardiac & Cardiovascular Systems

Cardiac monocytes and macrophages after myocardial infarction

Claire Peet et al.

CARDIOVASCULAR RESEARCH (2020)

Article Multidisciplinary Sciences

UTMD inhibit EMT of breast cancer through the ROS/miR-200c/ZEB1 axis

Dandan Shi et al.

SCIENTIFIC REPORTS (2020)

Article Engineering, Biomedical

Antagomir-155 Attenuates Acute Cardiac Rejection Using Ultrasound Targeted Microbubbles Destruction

Luyang Yi et al.

ADVANCED HEALTHCARE MATERIALS (2020)

Review Pharmacology & Pharmacy

Microbubbles and Nanobubbles with Ultrasound for Systemic Gene Delivery

Yoko Endo-Takahashi et al.

PHARMACEUTICS (2020)

Review Biochemistry & Molecular Biology

Galectin-3 in Cardiovascular Diseases

Valeria Blanda et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Review Multidisciplinary Sciences

Fibrosis: from mechanisms to medicines

Neil C. Henderson et al.

NATURE (2020)

Review Geriatrics & Gerontology

Roles of Biomarkers in Myocardial Fibrosis

Yuejia Ding et al.

AGING AND DISEASE (2020)

Article Multidisciplinary Sciences

Biomechanical assessment of remote and postinfarction scar remodeling following myocardial infarction

Mihaela Rusu et al.

SCIENTIFIC REPORTS (2019)

Review Biochemistry & Molecular Biology

Galectins as Molecular Targets for Therapeutic Intervention

Ruud P. M. Dings et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)

Review Cardiac & Cardiovascular Systems

Myocardial Interstitial Fibrosis in Heart Failure Biological and Translational Perspectives

Arantxa Gonzalez et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)

Review Biochemistry & Molecular Biology

Extracellular matrix remodeling and cardiac fibrosis

Li Li et al.

MATRIX BIOLOGY (2018)

Review Medicine, Research & Experimental

Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update

Navin Suthahar et al.

THERANOSTICS (2018)

Review Cardiac & Cardiovascular Systems

The Biological Basis for Cardiac Repair After Myocardial Infarction From Inflammation to Fibrosis

Sumanth D. Prabhu et al.

CIRCULATION RESEARCH (2016)

Review Cardiac & Cardiovascular Systems

Cardiac Fibrosis The Fibroblast Awakens

Joshua G. Travers et al.

CIRCULATION RESEARCH (2016)

Review Pharmacology & Pharmacy

Nucleic acid delivery with microbubbles and ultrasound

Joshua J. Rychak et al.

ADVANCED DRUG DELIVERY REVIEWS (2014)